![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TCF7L2 |
Gene summary for TCF7L2 |
![]() |
Gene information | Species | Human | Gene symbol | TCF7L2 | Gene ID | 6934 |
Gene name | transcription factor 7 like 2 | |
Gene Alias | TCF-4 | |
Cytomap | 10q25.2-q25.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9NQB0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6934 | TCF7L2 | CCI_1 | Human | Cervix | CC | 8.52e-09 | 1.07e+00 | 0.528 |
6934 | TCF7L2 | CCI_2 | Human | Cervix | CC | 2.84e-13 | 1.79e+00 | 0.5249 |
6934 | TCF7L2 | CCI_3 | Human | Cervix | CC | 3.90e-25 | 1.50e+00 | 0.516 |
6934 | TCF7L2 | T1 | Human | Cervix | CC | 2.62e-02 | 2.45e-01 | 0.0918 |
6934 | TCF7L2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.04e-16 | 1.10e+00 | -0.1808 |
6934 | TCF7L2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 6.23e-28 | 1.18e+00 | -0.0811 |
6934 | TCF7L2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.15e-04 | 6.75e-01 | -0.1088 |
6934 | TCF7L2 | HTA11_347_2000001011 | Human | Colorectum | AD | 7.40e-16 | 1.01e+00 | -0.1954 |
6934 | TCF7L2 | HTA11_411_2000001011 | Human | Colorectum | SER | 3.68e-14 | 1.80e+00 | -0.2602 |
6934 | TCF7L2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.47e-27 | 1.77e+00 | -0.2196 |
6934 | TCF7L2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 8.78e-05 | 5.97e-01 | -0.1207 |
6934 | TCF7L2 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.71e-15 | 9.81e-01 | -0.1526 |
6934 | TCF7L2 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.78e-11 | 1.02e+00 | -0.1464 |
6934 | TCF7L2 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.71e-08 | 8.85e-01 | -0.1001 |
6934 | TCF7L2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.56e-17 | 1.58e+00 | -0.059 |
6934 | TCF7L2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.16e-05 | 5.40e-01 | -0.1706 |
6934 | TCF7L2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.71e-07 | 6.82e-01 | -0.2061 |
6934 | TCF7L2 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.97e-02 | 4.47e-01 | -0.0842 |
6934 | TCF7L2 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.13e-15 | 1.20e+00 | 0.3487 |
6934 | TCF7L2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.08e-08 | 6.35e-01 | 0.281 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123310 | Cervix | CC | regulation of apoptotic signaling pathway | 96/2311 | 356/18723 | 4.08e-14 | 3.05e-11 | 96 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
GO:00506787 | Cervix | CC | regulation of epithelial cell proliferation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:005109810 | Cervix | CC | regulation of binding | 80/2311 | 363/18723 | 1.32e-07 | 6.42e-06 | 80 |
GO:200123410 | Cervix | CC | negative regulation of apoptotic signaling pathway | 56/2311 | 224/18723 | 1.39e-07 | 6.70e-06 | 56 |
GO:00608287 | Cervix | CC | regulation of canonical Wnt signaling pathway | 58/2311 | 253/18723 | 1.83e-06 | 5.89e-05 | 58 |
GO:009719110 | Cervix | CC | extrinsic apoptotic signaling pathway | 52/2311 | 219/18723 | 2.06e-06 | 6.34e-05 | 52 |
GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
GO:00468229 | Cervix | CC | regulation of nucleocytoplasmic transport | 31/2311 | 106/18723 | 2.68e-06 | 7.87e-05 | 31 |
GO:00903167 | Cervix | CC | positive regulation of intracellular protein transport | 41/2311 | 160/18723 | 3.24e-06 | 8.80e-05 | 41 |
GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
GO:00454445 | Cervix | CC | fat cell differentiation | 53/2311 | 229/18723 | 3.72e-06 | 9.75e-05 | 53 |
GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa052167 | Liver | Cirrhotic | Thyroid cancer | 23/2530 | 37/8465 | 4.63e-05 | 3.28e-04 | 2.02e-04 | 23 |
hsa04936 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa05165 | Liver | Cirrhotic | Human papillomavirus infection | 124/2530 | 331/8465 | 1.55e-03 | 7.83e-03 | 4.83e-03 | 124 |
hsa052107 | Liver | Cirrhotic | Colorectal cancer | 39/2530 | 86/8465 | 1.67e-03 | 8.01e-03 | 4.94e-03 | 39 |
hsa052138 | Liver | Cirrhotic | Endometrial cancer | 28/2530 | 58/8465 | 2.37e-03 | 1.00e-02 | 6.16e-03 | 28 |
hsa0516714 | Liver | Cirrhotic | Kaposi sarcoma-associated herpesvirus infection | 73/2530 | 194/8465 | 1.17e-02 | 3.81e-02 | 2.35e-02 | 73 |
hsa0513232 | Liver | Cirrhotic | Salmonella infection | 121/2530 | 249/8465 | 2.47e-10 | 5.13e-09 | 3.16e-09 | 121 |
hsa0452032 | Liver | Cirrhotic | Adherens junction | 52/2530 | 93/8465 | 1.36e-07 | 1.97e-06 | 1.21e-06 | 52 |
hsa0521612 | Liver | Cirrhotic | Thyroid cancer | 23/2530 | 37/8465 | 4.63e-05 | 3.28e-04 | 2.02e-04 | 23 |
hsa049361 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa051651 | Liver | Cirrhotic | Human papillomavirus infection | 124/2530 | 331/8465 | 1.55e-03 | 7.83e-03 | 4.83e-03 | 124 |
hsa0521012 | Liver | Cirrhotic | Colorectal cancer | 39/2530 | 86/8465 | 1.67e-03 | 8.01e-03 | 4.94e-03 | 39 |
hsa0521311 | Liver | Cirrhotic | Endometrial cancer | 28/2530 | 58/8465 | 2.37e-03 | 1.00e-02 | 6.16e-03 | 28 |
hsa0516715 | Liver | Cirrhotic | Kaposi sarcoma-associated herpesvirus infection | 73/2530 | 194/8465 | 1.17e-02 | 3.81e-02 | 2.35e-02 | 73 |
hsa0513242 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
hsa0521022 | Liver | HCC | Colorectal cancer | 65/4020 | 86/8465 | 8.85e-08 | 1.23e-06 | 6.87e-07 | 65 |
hsa0452042 | Liver | HCC | Adherens junction | 68/4020 | 93/8465 | 3.99e-07 | 4.46e-06 | 2.48e-06 | 68 |
hsa0521321 | Liver | HCC | Endometrial cancer | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
hsa052258 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
hsa0521622 | Liver | HCC | Thyroid cancer | 29/4020 | 37/8465 | 1.18e-04 | 5.88e-04 | 3.27e-04 | 29 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 4 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TCF7L2 | SNV | Missense_Mutation | c.413C>T | p.Ser138Phe | p.S138F | Q9NQB0 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
TCF7L2 | SNV | Missense_Mutation | novel | c.899N>T | p.Pro300Leu | p.P300L | Q9NQB0 | protein_coding | tolerated(0.19) | benign(0.425) | TCGA-AC-A6NO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TCF7L2 | SNV | Missense_Mutation | c.1255G>A | p.Ala419Thr | p.A419T | Q9NQB0 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TCF7L2 | SNV | Missense_Mutation | c.931N>T | p.His311Tyr | p.H311Y | Q9NQB0 | protein_coding | deleterious(0) | possibly_damaging(0.648) | TCGA-C8-A1HI-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
TCF7L2 | SNV | Missense_Mutation | c.614C>T | p.Thr205Met | p.T205M | Q9NQB0 | protein_coding | tolerated(0.12) | possibly_damaging(0.687) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TCF7L2 | SNV | Missense_Mutation | c.166C>G | p.Gln56Glu | p.Q56E | Q9NQB0 | protein_coding | tolerated(0.56) | possibly_damaging(0.756) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
TCF7L2 | SNV | Missense_Mutation | novel | c.1079A>G | p.Tyr360Cys | p.Y360C | Q9NQB0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A9UB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TCF7L2 | insertion | In_Frame_Ins | novel | c.535_536insCAC | p.Pro180dup | p.P180dup | Q9NQB0 | protein_coding | TCGA-C5-A7X3-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | ||
TCF7L2 | SNV | Missense_Mutation | c.1258C>T | p.Arg420Trp | p.R420W | Q9NQB0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-5M-AATA-01 | Colorectum | colon adenocarcinoma | Unknown | Unknown | I/II | Unknown | Unknown | Unknown | |
TCF7L2 | SNV | Missense_Mutation | c.1411N>T | p.Arg471Cys | p.R471C | Q9NQB0 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-A6-2681-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6934 | TCF7L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | sulfonamides, urea derivatives | 21114608,17519421 | ||
6934 | TCF7L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | tacrolimus | TACROLIMUS | 23041303,21857094 | |
6934 | TCF7L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | Dipeptidyl peptidase 4 (DPP-4) inhibitors | 27166975 | ||
6934 | TCF7L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | hydrochlorothiazide | HYDROCHLOROTHIAZIDE | ||
6934 | TCF7L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | cyclosporine | CYCLOSPORINE | 23041303,21857094 | |
6934 | TCF7L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | repaglinide | REPAGLINIDE | 20054294 | |
6934 | TCF7L2 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | sirolimus | SIROLIMUS | 23041303,21857094 |
Page: 1 |